Research programme: protease-activated monoclonal antibodies - CytomX Therapeutics

Drug Profile

Research programme: protease-activated monoclonal antibodies - CytomX Therapeutics

Alternative Names: CTLA-4 Probody Tx; CTLA-4-directed Probody™; CTX-023; CTX-033; CTX-1003; CX 188; CX 2005; EGFR Probody Drug Conjugate; J43 antibody; Probodies; Probody™ cancer therapeutics - Bristol-Myers Squibb

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CytomX Therapeutics
  • Developer Bristol-Myers Squibb; CytomX Therapeutics
  • Class Drug conjugates; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Epidermal growth factor receptor antagonists; Immunomodulators; Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Autoimmune disorders
  • Discontinued Inflammation

Most Recent Events

  • 28 Nov 2017 US FDA accepts IND application for CTLA-4-directed Probody™ for Cancer
  • 13 Nov 2017 CX 188 is still in preclinical development for Cancer in USA (Cytomx pipeline, November 2017)
  • 07 Nov 2017 CytomX plans to file an IND application with the US FDA of CX 188 in USA in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top